- This event has passed.
What does Psilocybin-Assisted Therapy for Depression Look Like? [ONLINE]
March 12 @ 12:00 pm - 1:00 pm
by Portland Psychotherapy
March 12th, 2021 – What does Psilocybin-Assisted Therapy for Depression Look Like? A Clinical Case Presentation based on a Recent Clinical Trial from Johns Hopkins with Alan K. Davis, Ph.D.
This talk will integrate findings from a recent controlled trial of psilocybin therapy for people diagnosed with Major Depressive Disorder with a case report from a patient enrolled in the trial. The efficacy of this intervention will be contextualized within the scope of the patient’s experiences and a description of the therapeutic process involved in preparing for and integrating psilocybin experiences as part of therapy.
Dr. Alan K Davis is an Assistant Professor of Social Work at The Ohio State University and Adjunct Assistant Professor in the Center for Psychedelic and Consciousness Research at Johns Hopkins University. Dr. Davis’s clinical experience includes working with people diagnosed with trauma-based psychological problems such as addiction, PTSD, depression, and anxiety. His clinical expertise includes providing evidenced-based treatments such as motivational interviewing, cognitive behavioral therapy, acceptance and commitment therapy, and psilocybin-assisted psychotherapy. Consistent with his clinical interests, his research interests, and expertise focus on contributing to the knowledge of and ability to help those suffering with substance use and mental health problems, understanding how to improve clinical outcomes through examining new treatments and developing ways to conceptualize substance use and mental health problems through a strengths-based approach. He recently completed a clinical trial of psilocybin therapy for major depressive disorder and current trials include exploring this treatment for patients with co-occurring alcohol use disorder and depression and patients with anorexia. He actively explores topics related to naturalistic psychedelic use among several populations including people of color who have experienced racial trauma, Spanish-speaking people, and people who use novel psychedelics such as 5-MeO-DMT.